CBD and the prostate: one human trial, and its limits

The CBD sold in shops is a hemp product, not a medicine. It has no authorisation for any prostate disease. The only authorised cannabidiol medicine, Epidyolex, is reserved for three rare forms of epilepsy. Our article on CBD and epilepsy tells the story of its approval.

A seller may therefore not present CBD as an answer to an enlarged prostate or to cancer. Regulation (EC) No 1924/2006 only allows authorised health claims on foods, and none concerns CBD. The French drug policy agency MILDECA points out that a CBD product may only claim a therapeutic effect if it is authorised as a medicine.

The two diseases are also unrelated. An enlarged prostate, or benign prostatic hyperplasia, is the most common benign tumour in men, according to French national health insurance. After 70, 37% of men have a form with urinary symptoms. An enlarged prostate does not increase the risk of prostate cancer.

Most of the work concerns cancer, and almost all of it takes place outside the human body. The table sums up the most cited studies.

The 2023 Irish study showed that CBD reduced the proliferation and invasion of cancer cells in culture. It was partly funded by a cannabis pharmaceutical company, as the authors declare. The 2024 American study gave 15 mg of CBD per kilo a day to mice grafted with human tumour cells. It reports slower progression and fewer recurrences over 30 and then 45 days. A mouse is not a patient: an effect seen in animals still has to be confirmed by trials in humans.

For an enlarged prostate, no human trial of CBD has been published. The closest work dates from 2011: CBD applied to isolated strips of bladder, in a laboratory bath, reduced their contractions. The authors themselves write that the result needs confirming in a living organism.

The University of Kentucky trial, published in 2023 in Cancers, followed 21 men whose PSA was rising again after surgery or radiotherapy. They took Epidyolex, the pharmaceutical CBD, at 600 then 800 mg a day for 90 days. There was no placebo group.

The primary endpoint was tolerability. The most frequent side effects were diarrhoea (55% of patients), nausea (25%) and fatigue (20%), all grade 1 or 2, meaning mild to moderate. After 12 weeks, PSA was stable in 16 of the 18 patients assessed, partially down in one and up in another. Without a control group, these figures say nothing about an effect of CBD. The authors only conclude that 800 mg a day is a tolerated dose for future studies.

Compare that dose with shop products. In February 2026 EFSA published a provisional safe level of about 2 mg of CBD a day for a 70 kg adult. The trial's 600 to 800 mg are 300 to 400 times more, under medical supervision. Our article on what CBD clinical trials really show puts this gap in the context of the wider research.

French national health insurance lists the typical symptoms of an enlarged prostate: frequent need to urinate day and night, weak or interrupted stream, feeling that the bladder is not empty, leaks between visits to the toilet. They are not specific to an enlarged prostate. An infection, a bladder problem or a cancer can cause similar signs.

Hence the value of a diagnosis: clinical examination, urine test, sometimes an ultrasound or a urine flow measurement. A PSA test is used when cancer is suspected. Suddenly being unable to urinate, with a full and painful bladder, is called acute urinary retention: it is an emergency that needs immediate treatment.

Delaying that consultation in favour of a wellness product is the real risk behind this online search. No CBD product replaces a diagnosis.

The main medicines for an enlarged prostate are alpha-blockers (alfuzosin, doxazosin, tamsulosin, terazosin) and 5-alpha-reductase inhibitors (dutasteride, finasteride), as French national health insurance explains.

CBD inhibits several liver enzymes of the cytochrome P450 family, including CYP3A4 and CYP2D6, according to a review in Frontiers in Psychiatry. The professional leaflet for tamsulosin states that these two enzymes handle its metabolism, and that inhibiting them could increase exposure to it. The same leaflet gives an order of magnitude: combined with ketoconazole, a strong CYP3A4 inhibitor, tamsulosin exposure is multiplied by 2.8. Its known side effect is a drop in blood pressure on standing up, which can lead to fainting.

The interaction remains theoretical at the low doses of a shop product, but nobody has measured it. If you take a prostate treatment, or any other medicine, mention CBD to your doctor or pharmacist before using it. Bring the product and its certificate of analysis. Our article on CBD's grapefruit effect explains this mechanism, and the one on CBD for older adults lists the precautions specific to that age.